wallstreetGenny
Posted - 48 minutes ago
@DavidScott $gnpx $drug $VKTX Cancer and diabetes gene therapy with mesothelioma and glioblastoma data this wednesday….
Stocks_only_go_upp
Posted - 1 hour ago
$VKTX tightest coil on a a bio stock I’ve seen in a minute Nearly every time I’ve seen a stock trade like this in a tight > sideways there’s an explosive move to the upside Its coming load the house , the wife, the kids, ALL IN
Elevator_up
Posted - 1 hour ago
$VKTX The goose 🪿 is on the loose. Since you seem to be presenting yourself as an expert on the future value of the stock price. Can we get you on record for end of the day 11/4? How about the opening on 10/24? Just ballpark…
snowgoose2000
Posted - 2 hours ago
$VKTX -Promising pipeline and upcoming developments. Are you kidding me? That quote has been use by most if not all promising small bio companies. Too funny, you’ll see the share price is already built in for any potential good news
ChessGM
Posted - 2 hours ago
$VKTX Upcoming earnings: 10/23/2024, Bullish (8.3) Viking Therapeutics, Inc. has been generating significant interest in the biotech sector, particularly in the context of its promising pipeline and upcoming developments. Recent articles indicate that the company's stock has performed well, exceeding market returns and experiencing a notable rise of 29% over the past three months. The bullish sentiment surrounding VKTX is largely driven by positive updates from its clinical trials, particularly for its novel weight-loss treatments, which analysts believe position the company favorably against established competitors like Novo Nordisk and Eli Lilly. Wall Street analysts maintain an optimistic outlook, with many recommending VKTX as a buy, supported by JPMorgan's overweight rating and a price target of $80 per share. This enthusiasm is bolstered by increasing institutional ownership, suggesting that large investors are confident in Viking's future prospects. However, the recent reduction in holdings by State Street Corp raises some questions about the stock's immediate trajectory, although it appears to be more of a strategic portfolio adjustment rather than a bearish signal. Viking Therapeutics is set to report its third-quarter financial results on October 23, 2024. Investors are keenly anticipating this release, as it will provide insights into the company's ongoing trials and future pipeline developments. Given that Viking is currently in the spotlight for its innovative treatments, the upcoming earnings report will likely focus on advancements in its clinical programs, especially those related to metabolic and endocrine disorders. Investors are hopeful that the results will reflect positively on the company's performance and potentially impact its stock price favorably. Follow us! Do not miss other earnings alerts from ChessGM.
Jackie_O_
Posted - 2 hours ago
$VKTX 🦗🦗🦗
Drewstrong
Posted - 4 hours ago
@Magnificient $ALT $VKTX Hey Magnificent, just like ur mom!!! Go ALT!
uknic
Posted - 7 hours ago
$VKTX our day will come soon. Patience Vikings
snowgoose2000
Posted - 8 hours ago
$VKTX Very nice close today as it closed towards the low of the day and closer to $60 than $70 and will tic lower. News is out, earnings out Wednesday but there are no earnings $62.10
Elevator_up
Posted - 8 hours ago
$VKTX Question posed on X today:
Are any/all of $VKTX's submissions for Obesity Week under embargo until 11/3 (when embargoes are lifted) such that the company will be limited in what it can say at its coming quarterly reporting this week?
A: Company can't share the data because it's embargoed.. but they can definitely provide vague hints. Like the data was amazing.. best in class. Etc.
• Don’t take it as Gospel- but it seems accurate due to these guidelines:
https://obesityweek.org/abstracts/embargo-policy/
Enthropy_22
Posted - 8 hours ago
$VKTX no volume day, MMs traded with themselves all day, ran 65 stops on shorts and ran 64 stops on longs. Business as usual.
TrustButVerifi
Posted - 8 hours ago
$VKTX No Oral meds will Ever replace SubQ GLP-1/GIP! Never! Lilly's Tirzepatide is the king til it gets dethroned by Viking VK2735! VKTX is the most Undervalued Derisked Biotech on the Planet!
vu_jade
Posted - 8 hours ago
$VKTX when it’s this quiet market makers try to steal shares ..
Magnificient
Posted - 8 hours ago
$VKTX best in Class? ORAL
Quantumup
Posted - 8 hours ago
BMO Capital reiterated $GPCR OP/$100 BMO has⬆️confidence in the total obesity📗('1290/apelin/amylin) after 19🌍🛣️meetings, w/ 24 investor accounts/ $GPCR MGMT—BMO left w/⬆️confidence in $GPCR given its leadership position in the oral GLP1 space/rapid devt of small molecules🎯g apelin/of>importance amylin: $vktx $tern $lly
BeyondtheCouch
Posted - 9 hours ago
$VKTX assuming everyone knows that as well as oral update, Viking are likely to share 6w follow up date on Venture study which will prove monthly SubQ dosing is practical 👍
aleric44
Posted - 9 hours ago
$VKTX every time we get close to 65 today the MMs hit the sell button
Idvst8
Posted - 10 hours ago
$VKTX The upside from this level is still Juicy. Oral data Should be STELLAR !!! Not good, but amazing.
Elevator_up
Posted - 10 hours ago
$VKTX Regarding SC VK2735, we’re expecting detailed data from the Phase 2 VENTURE trial to build on the impressive topline results announced in February, which showed an impressive ~13% placebo-adjusted weight loss in 13 weeks with a generally clean safety/tolerability profile. We expect that the VENTURE data presentation at ObesityWeek will include new data from the 6-week follow-up period, which we suspect will be supportive of $VKTX prior commentary to explore monthly dosing – a potentially significant differentiator that could add real-world flexibility. VKTX has guided to advancing SC VK2735 directly into a Phase 3 program pending an end-of-phase 2 (EOP2) meeting with FDA in 2H24...."
(Part 2 of 2)
Elevator_up
Posted - 10 hours ago
$VKTX Leerink:" ObesityWeek 2024 Preview: $VKTX will present two late-breaking posters on November 3rd featuring new clinical data for both oral and SC VK2735 – we expect these data will build on initial results showing compelling weight loss and an attractive safety/tolerability profile. Based on the data presented to date, we view oral VK2735 as a top contender among the oral obesity landscape, and believe that strong data at ObesityWeek could further strengthen $VKTX’s strategic value. At the conference, we will be looking for further dose-dependent weight reductions with the higher dose cohorts, while maintaining a well-tolerated and potentially differentiated safety/tolerability profile via less frequent and/or milder GI AEs relative to competing oral compounds.
(Part 1 of 2)
Maverick11
Posted - 10 hours ago
$VKTX Watching fits/starts here on VKTX. Expect they will let her loose and it will make a move ahead of Wed… $ASPI and $RKLB doing well in top names. $ASPI on fire. I added 2 trading names today - not typical Mav picks but bought 5k shares of $AMBI to put away and shares/calls of $LGIH - both spec/special situations. Good luck all - mav
Enthropy_22
Posted - 10 hours ago
$VKTX sits right on 20 EMA daily support blue line
vu_jade
Posted - 11 hours ago
$VKtX slow day today
CRYPTO_BLONDE_GIRL
Posted - 11 hours ago
$VKTX These Alerts are 🔥!
Stocks4thought
Posted - 11 hours ago
$ELDN Should do me for $.35 gain, ot $SGMT $VKTX $SLNO $BWAY
Booger_McFarland
Posted - 11 hours ago
$VKTX Fortune favors the bold
biolover
Posted - 11 hours ago
$Vktx $Rhhby $amgn Roche running now phase 2 trials on their glp1 drug for finish in 2026. Phase 3 will not start till late 26 or 2027. That means Roche is now minimum 1.5 years behind Viking with a drug that is more toxic and potentially even less effective The big bust will unfold later this year with Amgen likely disappointing data . They have not even commented on a date for phase 3
Chi_Booth
Posted - 12 hours ago
$VKTX Added 2k shares on the dip. Now fully loaded for the ER and OW.
Elevator_up
Posted - 13 hours ago
$VKTX Careful with your fowl noise Goose 🪿- don’t get trapped when this bolts North. BTW: Yer awful quiet on Green Day’s like Friday 😊